Putnam Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Putnam Investments’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-336,700	Closed	-$26.9M	–	1237
2022 Q2	$26.9M	Buy	336,700 +188,200	+127%	+$17.8M	0.05%	178
2022 Q1	$15.6M	Buy	+148,500	New	+$14.5M	0.02%	262
2020 Q4	–	Sell	-124,584	Closed	-$9.68M	–	906
2020 Q3	$9.68M	Sell	124,584 -24,463	-16%	-$1.68M	0.02%	346
2020 Q2	$8.28M	Sell	149,047 -3,079	-2%	-$132K	0.02%	360
2020 Q1	$4.51M	Sell	152,126 -640	-0.4%	-$21.7K	0.01%	458
2019 Q4	$5.53M	Buy	+152,766	New	+$4.68M	0.01%	488
2017 Q2	–	Sell	-124,504	Closed	-$1.84M	–	1380
2017 Q1	$1.84M	Sell	124,504 -14,166	-10%	-$229K	﹤0.01%	883
2016 Q4	$2.24M	Sell	138,670 -1,497	-1%	-$27.1K	0.01%	819
2016 Q3	$2.54M	Sell	140,167 -128,064	-48%	-$2.5M	0.01%	776
2016 Q2	$4.42M	Buy	+268,231	New	+$4.34M	0.01%	673
2015 Q2	–	Sell	-91,420	Closed	-$2.38M	–	1580
2015 Q1	$2.38M	Buy	+91,420	New	+$1.68M	﹤0.01%	1004

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Putnam Investments's HZNP Position: Q3 2022 in Review

Putnam Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 336,700 shares — an estimated $26.9M sold.

Putnam Investments first reported a position in HZNP in Q1 2015 and held it in 11 quarters. The position peaked at $26.9M in Q2 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Putnam Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Putnam Investments sold 336,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $26.9M.
Putnam Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 11 quarters.
Putnam Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $26.9M in Q2 2022.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Putnam Investments's 13F filing for Q3 2022, filed 14 Nov 2022.